Skip to main content
. 2023 Apr 13;15(8):2273. doi: 10.3390/cancers15082273

Figure 1.

Figure 1

Overview of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. Key elements on predictive biomarker progress for the efficacy of immune checkpoint inhibitors therapy are briefly precented in the figure, including PD-L1, dMRR/MSI, TMB, EBV-positive status, tumor immune microenvironment (TIME), specific genetic mutation, gut microbiota, liquid biopsy biomarkers.